Curaleaf (OTCMKTS:CURLF) Issues Earnings Results

Curaleaf (OTCMKTS:CURLF) issued its quarterly earnings results on Thursday. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.03, Zacks reports. The company had revenue of $333.07 million during the quarter, compared to analysts’ expectations of $328.70 million. Curaleaf had a negative net margin of 18.08% and a negative return on equity of 22.49%.

Curaleaf Stock Down 4.2%

Curaleaf stock opened at $2.33 on Friday. The stock has a market cap of $1.58 billion, a PE ratio of -7.77 and a beta of 0.74. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.47 and a quick ratio of 0.71. The stock’s fifty day moving average is $2.50 and its two-hundred day moving average is $2.70. Curaleaf has a 1-year low of $0.68 and a 1-year high of $5.05.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on CURLF shares. Alliance Global Partners reiterated a “buy” rating on shares of Curaleaf in a research note on Monday, December 22nd. Zacks Research raised Curaleaf from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Finally, ATB Cormark Capital Markets upgraded Curaleaf to an “outperform” rating in a research note on Tuesday, December 2nd. Two analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy”.

About Curaleaf

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.